Skip to main content

Entyvio Disease Interactions

There are 4 disease interactions with Entyvio (vedolizumab).

Major

Immunosuppressive agents (applies to Entyvio) infections

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents. Patients receiving immunosuppressants are at increased risk of developing bacterial, viral, fungal, and protozoal infections, and new or reactivated viral infections including opportunistic infections. Caution should be exercised when considering their use in patients with severe or chronic infections. It is recommended to interrupt therapy in patients who develop a new infection while undergoing treatment and to monitor these patients closely for any sign or symptom indicative of infection.

References

  1. (2001) "Product Information. Rapamune (sirolimus)." Wyeth-Ayerst Laboratories
  2. (2007) "Product Information. Soliris (eculizumab)." Alexion Pharmaceuticals Inc
  3. (2011) "Product Information. Nulojix (belatacept)." Bristol-Myers Squibb
  4. (2012) "Product Information. Aubagio (teriflunomide)." Genzyme Corporation
  5. (2014) "Product Information. Entyvio (vedolizumab)." Takeda Pharmaceuticals America
  6. (2017) "Product Information. Mycophenolic Acid (mycophenolic acid)." Apotex Corporation
  7. (2018) "Product Information. Gamifant (emapalumab)." Sobi Inc
  8. (2021) "Product Information. Lupkynis (voclosporin)." Aurinia Pharma
  9. (2021) "Product Information. Saphnelo (anifrolumab)." Astra-Zeneca Pharmaceuticals
View all 9 references
Major

Immunosuppressive agents (applies to Entyvio) PML

Major Potential Hazard, Moderate plausibility. Applicable conditions: Immunodeficiency

Immunosuppressive agents may increase the risk of progressive multifocal leukoencephalopathy (PML). Certain agents are contraindicated in patients who have or have had PML. Patients receiving chronic immunosuppressant or immunomodulatory therapy or who have systemic medical conditions resulting in significantly compromised immune system function should not be treated with these agents. Health care professionals should monitor patients for any new sign or symptom suggestive of PML. Therapy dosing should be withheld immediately and an appropriate diagnostic evaluation should be performed at the first sign or symptom suggestive of PML.

References

  1. (2001) "Product Information. Rapamune (sirolimus)." Wyeth-Ayerst Laboratories
  2. (2004) "Product Information. Tysabri (natalizumab)." Elan Pharmaceutical/Athena Neurosciences Inc
  3. (2007) "Product Information. Soliris (eculizumab)." Alexion Pharmaceuticals Inc
  4. (2011) "Product Information. Nulojix (belatacept)." Bristol-Myers Squibb
  5. (2012) "Product Information. Aubagio (teriflunomide)." Genzyme Corporation
  6. (2014) "Product Information. Entyvio (vedolizumab)." Takeda Pharmaceuticals America
  7. (2017) "Product Information. Mycophenolic Acid (mycophenolic acid)." Apotex Corporation
View all 7 references
Major

Vedolizumab (applies to Entyvio) liver disease

Major Potential Hazard, Moderate plausibility.

Elevated transaminase levels with or without elevated bilirubin have occurred in patients who received vedolizumab. Care should be exercised when using this agent in patients predisposed to liver injury. Do not use vedolizumab in patients with jaundice or other evidence of significant liver injury.

References

  1. (2014) "Product Information. Entyvio (vedolizumab)." Takeda Pharmaceuticals America
Moderate

Vedolizumab (applies to Entyvio) vaccination

Moderate Potential Hazard, Moderate plausibility.

Prior to initiating treatment with vedolizumab, all patients should be brought up to date with all immunizations per current immunization guidelines. Patients receiving vedolizumab may receive non-live vaccines (e.g., influenza vaccine injection) and may receive live vaccines if the benefits outweigh the risks. Caution and close monitoring is recommended as there are no data on the secondary transmission of infection by live vaccines in patients receiving vedolizumab.

References

  1. (2014) "Product Information. Entyvio (vedolizumab)." Takeda Pharmaceuticals America

Entyvio drug interactions

There are 152 drug interactions with Entyvio (vedolizumab).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer